Fischer Medical Ventures Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fischer Medical Ventures Limited reported standalone revenue of Rs.1,739.18 lakhs for FY26, a massive jump from Rs.521.97 lakhs in FY25 — over 3x growth driven by a shift toward traded goods (purchase of traded goods at Rs.1,195.68L vs Rs.461.06L). However, the company swung to a net loss of Rs.1,042.29 lakhs (vs profit of Rs.66.32L in FY25), as total expenses surged to Rs.3,139.11L (vs Rs.771.58L). Finance costs spiked sharply to Rs.465.23L (vs Rs.13.17L), and other expenses jumped to Rs.1,244.27L. The company posted negative operating cash flow of Rs.572.17L. The board recommended a dividend of Rs.0.05 per share and appointed S. Ramanand Aiyer & Co. as internal auditors for FY27. Auditors issued an unmodified (clean) opinion.
The stock shows a dramatic revenue surge but a severe loss-making situation with negative cash flow and soaring finance costs — a red flag despite top-line growth. Shareholders face risk given the operational loss and cash burn, though clean audit opinion provides some assurance on financial reporting quality.